Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
Features and Benefits
This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 10(4), 198-200 (2010-12-17)
The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). The present study was a 12-week, prospective, structured clinical trial of blonanserin for the treatment
Blonanserin for the treatment of delirium patients at an emergency medical care center: an open-label study.
Koji Kato et al.
Asian journal of psychiatry, 6(2), 182-183 (2013-03-08)
Improvement in quetiapine-induced hypoglycemia following a switch to blonanserin.
Yutaro Suzuki et al.
Psychiatry and clinical neurosciences, 66(4), 370-371 (2012-05-26)
Journal of psychiatric research, 47(2), 149-154 (2012-11-08)
There is uncertainty about the efficacy and tolerability of blonanserin in schizophrenia. PubMed, the Cochrane Library databases, PsycINFO, and Google Scholar were searched up to September 2012. A systematic review and meta-analysis of individual patient data from randomized, controlled trials
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 903, 46-52 (2012-07-24)
Blonanserin is a novel atypical antipsychotic with highly selective receptor antagonist activity to dopamine D₂ and 5-HT(2A). N-desethyl blonanserin (blonanserin C) is its major active metabolite in human plasma. Herein we report a new highly sensitive, selective, and rapid liquid
We offer many products related to serotonin receptors for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.